Adverse events1,395

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,395

Type	Event	Organ system	Group	Affected	At risk
other	Anaemia	Blood and lymphatic system disorders	Arm A1: Investigator Choice - Gem/Nab-Based Chemotherapy	9	21
other	Anaemia	Blood and lymphatic system disorders	Arm A2: Investigator Choice - 5 FU-Based Chemotherapy	5	19
other	Anaemia	Blood and lymphatic system disorders	Arm B: Cabiralizumab + Nivolumab	13	49
other	Anaemia	Blood and lymphatic system disorders	Arm C: Cabiralizumab + Nivolumab + Gemcitabine-Based Chemotherapy	34	48
other	Anaemia	Blood and lymphatic system disorders	Arm D: Cabiralizumab + Nivolumab + 5-FU-Based Chemotherapy	17	42
other	Leukopenia	Blood and lymphatic system disorders	Arm A1: Investigator Choice - Gem/Nab-Based Chemotherapy	0	21
other	Leukopenia	Blood and lymphatic system disorders	Arm A2: Investigator Choice - 5 FU-Based Chemotherapy	0	19
other	Leukopenia	Blood and lymphatic system disorders	Arm B: Cabiralizumab + Nivolumab	0	49
other	Leukopenia	Blood and lymphatic system disorders	Arm C: Cabiralizumab + Nivolumab + Gemcitabine-Based Chemotherapy	3	48
other	Leukopenia	Blood and lymphatic system disorders	Arm D: Cabiralizumab + Nivolumab + 5-FU-Based Chemotherapy	1	42
other	Lymphopenia	Blood and lymphatic system disorders	Arm A1: Investigator Choice - Gem/Nab-Based Chemotherapy	0	21
other	Lymphopenia	Blood and lymphatic system disorders	Arm A2: Investigator Choice - 5 FU-Based Chemotherapy	0	19
other	Lymphopenia	Blood and lymphatic system disorders	Arm B: Cabiralizumab + Nivolumab	0	49
other	Lymphopenia	Blood and lymphatic system disorders	Arm C: Cabiralizumab + Nivolumab + Gemcitabine-Based Chemotherapy	3	48
other	Lymphopenia	Blood and lymphatic system disorders	Arm D: Cabiralizumab + Nivolumab + 5-FU-Based Chemotherapy	1	42
other	Neutropenia	Blood and lymphatic system disorders	Arm A1: Investigator Choice - Gem/Nab-Based Chemotherapy	2	21
other	Neutropenia	Blood and lymphatic system disorders	Arm A2: Investigator Choice - 5 FU-Based Chemotherapy	0	19
other	Neutropenia	Blood and lymphatic system disorders	Arm B: Cabiralizumab + Nivolumab	0	49
other	Neutropenia	Blood and lymphatic system disorders	Arm C: Cabiralizumab + Nivolumab + Gemcitabine-Based Chemotherapy	13	48
other	Neutropenia	Blood and lymphatic system disorders	Arm D: Cabiralizumab + Nivolumab + 5-FU-Based Chemotherapy	6	42

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03336216/events

API reference For AI assistants

Adverse events1,395

Sources 3

Read this list from software.